תראקאפ 131
Country: Iżrael
Lingwa: Ebrajk
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
SODIUM IODIDE (131 I)
Disponibbli minn:
ELDAN ELECTRONIC INSTRUMENTS CO LTD, ISRAEL
Kodiċi ATC:
V09FX03
Għamla farmaċewtika:
קפסולה קשיחה
Kompożizzjoni:
SODIUM IODIDE (131 I) 37 - 5550 MBQ
Rotta amministrattiva:
פומי
Tip ta 'preskrizzjoni:
מרשם נדרש
Manifatturat minn:
GE HEALTHCARE BUCHLER GmbH & Co. KG
Grupp terapewtiku:
SODIUM IODIDE (131I)
Żona terapewtika:
SODIUM IODIDE (131I)
Indikazzjonijiet terapewtiċi:
Theracap 131 is a radioiodine thyroid therapy indicated for: 1. Treatment of Graves' disease, as well as focal or disseminated autonomies of the thyroid.2.Treatment of papillary and follicular thyroid carcinomas including metastases. - Whole-body-scintigraphy for monitoring papillary or follicular thyroid carcinoma. Sodium iodide 131 therapy is often combined with surgical intervention and with antithyroid medications.
Data ta 'l-awtorizzazzjoni:
2015-09-30
